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Adherence to Analgesics for Cancer Pain: A Comparative Study of African
Americans and Whites Using an Electronic Monitoring Device
Abstract
Despite well-documented disparities in cancer pain outcomes among African Americans, surprisingly little
research exists on adherence to analgesia for cancer pain in this group. We compared analgesic adherence for
cancer-related pain over a 3-month period between African Americans and whites using the Medication Event
Monitoring System (MEMS). Patients (N = 207) were recruited from outpatient medical oncology clinics of
an academic medical center in Philadelphia (≥18 years of age, diagnosed with solid tumors or multiple
myeloma, with cancer-related pain, and at least 1 prescription of oral around-the-clock analgesic). African
Americans reported significantly greater cancer pain (P < .001), were less likely than whites to have a
prescription of long-acting opioids (P < .001), and were more likely to have a negative Pain Management
Index (P < .001). There were considerable differences between African Americans and whites in the overall
MEMS dose adherence, ie, percentage of the total number of prescribed doses that were taken (53% vs 74%, P
< .001). On subanalysis, analgesic adherence rates for African Americans ranged from 34% (for weak opioids)
to 63% (for long-acting opioids). Unique predictors of analgesic adherence varied by race; income levels,
analgesic side effects, and fear of distracting providers predicted analgesic adherence for African Americans
but not for whites. Perspective: Despite evidence of disparities in cancer pain outcomes among African
Americans, surprisingly little research exists on African Americans' adherence to analgesia for cancer pain.
This prospective study uses objective measures to compare adherence to prescribed pain medications between
African American and white patients with cancer pain.
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Abstract
Despite well-documented disparities in cancer pain outcomes among African Americans, 
surprisingly little research exists on adherence to analgesia for cancer pain in this group. We 
compared analgesic adherence for cancer-related pain over a 3-month period between African 
Americans and Whites using Medication Event Monitoring System [MEMS]. Patients (n=207) 
were recruited from outpatient medical oncology clinics of an academic medical center in 
Philadelphia [≥18 years of age, diagnosed with solid tumors or multiple myeloma, with cancer-
related pain, and at least one prescription of oral around-the-clock analgesic (ATC)]. African 
Americans reported significantly greater cancer pain (P<.001), were less likely than Whites to 
have a prescription of long acting opioids (P<.001), and more likely to have a negative pain 
management index (P<.001). There were considerable differences between African Americans and 
Whites in the overall MEMS dose adherence, i.e., percentage of the total number of prescribed 
doses that were actually taken (53% vs. 74%, P<.001). On sub-analysis, analgesic adherence rates 
for African Americans ranged from 34% (for weak opioids) to 63% (for long acting opioids). 
Unique predictors of analgesic adherence varied by race; income levels, analgesic side-effects, and 
fear of distracting providers predicted analgesic adherence for African Americans but not for 
Whites.
Corresponding Author: Salimah H. Meghani, PhD, MBE, RN, FAAN, Associate Professor, Department of Biobehavioral Health 
Sciences, NewCourtland Center for Transitions & Health, University of Pennsylvania School of Nursing, Associate Fellow, Center for 
Bioethics, Claire M. Fagin Hall, 418 Curie Boulevard, Room 337, Philadelphia, PA 19104-4217, Tel: (215) 573-7128, Fax: (215) 
573-7507, meghanis@nursing.upenn.edu. 
Presented in part at the 32nd Annual Scientific Meeting of the American Pain Society, New Orleans, May 8–11, 2013.
Conflicts of Interest:
No authors declared any financial or non-financial conflicts of interest.
Disclosures:
Supported by NIH Challenge Grant to Dr. Salimah Meghani (NIH/NINR RC1-NR011591).
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
J Pain. Author manuscript; available in PMC 2016 September 01.
Published in final edited form as:
J Pain. 2015 September ; 16(9): 825–835. doi:10.1016/j.jpain.2015.05.009.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Introduction
The Institute of Medicine (IOM) report, Relieving Pain in America, finds that one of the 
most robust findings on differential pain outcomes pertain to African Americans.16 Previous 
IOM reports41, accumulated reviews, 1, 8, 11, 12, 26 and a meta-analysis,23 compelingly 
demonstrates that African American patients are less likely to receive analgesia for pain in 
cancer and non-cancer settings. There is also strong evidence from studies conducted 
independently in different geographical regions in the United States (U.S.) that pharmacies 
in predominantly African American and minority zip codes do not carry opioids needed to 
treat moderate to severe pain.13,30
While provider and system level factors have been documented in the literature, suprisingly 
little is known about adherence to analgesia for cancer pain among African Americans. This 
issue is important since analgesics remain the predominant and consistently reimbursable 
clinical paradigm for managing cancer pain. While the National Comprehensive Cancer 
Network guidelines for adult cancer pain31 include a number of complementary and 
alternative modalities, they are not consistently reimbursed or lack rigorous data on clinical 
effectiveness for cancer pain.4,20 Thus differential analgesic adherence may be 
conceptualized as an important explanatory variable in cancer pain outcomes.28
The majority of the studies on analgesic adherence for cancer pain have been conducted 
predominantly or exclusively with White samples.27, 28, 32, 43, 47, 53, 55 The very limited 
existing studies with African Americans are cross-sectional (e.g., computed adherence for 
the past 24 hours)38 and are based on self-reported measures of adherence.2, 22, 38, 50 Studies 
in non-cancer settings, comparing self-reported measures of adherence with objective 
measures such as electronic monitoring, have found that subjective adherence measures are 
not sufficiently accurate and overestimate rates of adherence by 10%–30%.3, 7, 10, 14, 19, 54 
Thus, we compared analgesic adherence for cancer pain between African Americans and 
Whites longitudinally using Medication Event Monitoring System [MEMSTM]. The specific 
aims were to:
1. Compare adherence to prescribed around-the-clock (ATC) analgesic between 
African Americans and Whites with cancer-related pain over a 3-month period.
2. Identify unique predictors of ATC analgesic adherence for cancer pain for African 
Americans and Whites.
Methods
Design and Study Population
The study was a 3-month observational design with repeated measures at two time-points, 
i.e., baseline (T1) and 3-months (T2). Patients were recruited from two outpatient medical 
oncology clinics of an academic medical center in Philadelphia between December 2009- 
August 2011. Inclusion was based on self-identified African Americans or Whites, at least 
18 years of age, diagnosed with solid tumors or multiple myeloma, with cancer-related pain, 
and at least one prescription of oral ATC analgesic. Patients were excluded if they were 
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prescribed ATC analgesics using a transdermal system (e.g. fentanyl patch) due to 
limitations of MEMS vials. The study was approved by the Institutional Review Board of 
the University of Pennsylvania and all patients provided informed consent.
Study Measures
Index Analgesic—The information regarding prescribed ATC analgesics (index 
medication) was gathered based on patient self-report during the baseline T1 interview and 
triangulated with electronic medical records review. Index analgesics were coded according 
to the World Health Organization’s (WHO) analgesic ladder. 51, 52 This includes Step 1 
(non-opioid analgesics e.g., ibuprofen, acetaminophen, naproxen); Step 2 (weak opioids e.g., 
codeine); and Step 3 (strong opioids (e.g., morphine, oxycodone, methadone). The Step 3 
analgesics were further coded according to immediate release and extended or sustained 
release (long acting) opioids due to evidence of both differential prescription and use of long 
acting opioids by race.50 We computed Pain Management Index (PMI) for each patient 
based on WHO guidelines for treating cancer pain.51, 52 The PMI measure is based on the 
most potent analgesic prescribed to a patient relative to the level of their reported pain. PMI 
is calculated by subtracting patient’s pain levels (“pain worst” score from the Brief Pain 
Inventory coded as mild, moderate, or severe) from the most potent analgesia prescribed. A 
negative PMI implies inadequate analgesic prescription relative to the reported pain level.
MEMS Analgesic Adherence—Analgesic adherence was captured using [MEMSTM 
AARDEX Group Ltd]. MEMS is a medication bottle cap with a microprocessor that records 
the occurrence and time of bottle opening in real time. The primary measure of ATC 
analgesic adherence in our study was “dose adherence” (percentage of the total number of 
prescribed doses that were actually taken). For example, if a patient took 60 out of 80 
prescribed doses over the study period, ‘dose adherence’ measure would be 75%.
Patients were instructed on the correct use of MEMS bottle during the baseline T1 interview. 
A follow-up phone call was made to each participant within 7 days of the T1 to allow 
participants to ask any questions they may have about proper usage of the MEMS bottle. 
Patients were instructed to use the bottle for the duration of the study period, and only use 
the bottle to take the index medication including any refills for the index medication. They 
were asked to notify the study staff of any changes in the medication dose or frequency as 
well as document this information in a medication log, where they also maintained a record 
of any instances of bottle opening other than when taking the index medications.
The PowerView software was used to record and compute MEMS adherence. If a frequency 
or medication change occurred during the study period, a new medication entry (phase) was 
created as a denominator, with the previous phase ending at PowerView’s default time, 
2:59am the day of the change and the next phase beginning at 3:00am. If a dosage change 
occurred, the average of the two (or more) dosages was reported, and no new phase was 
created. If a patient reported (in writing on the event log or verbally with reasonable 
certainty during the T2 interview) having taken doses that the bottle did not record, the 
events were added to the MEMS data. For example, added events might occur if a patient 
took out two pills at one time and took the second later in the day, or if the patient took out 6 
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pills for a 3-day trip. Likewise, if a patient reported extra openings for reasons other than 
taking the medication, the extra openings were excluded from the MEMS adherence 
calculation. Excluded events included accidental openings, openings only to count pills or 
refill the bottle.
Also, hospitalization periods were adjusted in the analysis as a non-monitored period 
beginning on the calendar day of admission at 3:00am and ending on the calendar day after 
discharge at 2:59am. Hospitalization information (including facility name, dates, and 
primary and secondary diagnoses) was obtained from self-report between the T1 and T2 
dates, self-report at the T2 interview, and review of patient charts. Hospitalization duration 
was calculated by subtracting the admission date from the discharge date.
Self-reported Analgesic Barriers—Barriers Questionnaire-II49 was used at baseline to 
assess patients’ beliefs about management of cancer pain. BQ-II is a 27 item instrument that 
elicits pain management concerns in 8 domains: 1) fear of addiction, 2) fear of tolerance, 3) 
fear of side effects, 4) fatalism about cancer pain, 5) desire to be a good patient, 6) fear of 
distracting health provider from treating cancer, 7) fear that the analgesics impair the 
immune system and 8) concern that analgesics may mask ability to monitor illness 
symptoms. For each item, the responses range from 0 (do not agree) to 5 (agree very much). 
The recommended scoring is based on mean scores on the total scale (27-items) and 
subscales. The internal consistency of the scale is excellent at 0.8949.
Analgesic Side-effects—Analgesic side-effects were captured at baseline using 
Medication Side-effects Checklist (MSEC)48 that elicits information on presence, type and 
severity of eight common analgesic side-effects during the past week (0–10; no severity-
extreme severity). The reported internal consistency reliability (Cronbach’s alpha) is greater 
than 0.80.
Pain Severity and Pain Impact—Pain severity and pain impact was measured at 
baseline using the Brief Pain Inventory (BPI).9 The tool assesses pain at its worst, least, 
average over the past week and pain currently experienced (pain now) on a 0–10 scale (no 
pain-pain as bad as you can imagine). The psychometrics of the BPI is well-established with 
cancer patients, including minority patients with cancer. Its Cronbach’s alpha ranges 0.77 to 
0.91.
Intentional vs. Unintentional Non-adherence—Morisky Medication Adherence Scale 
(MMAS),29 a structured, 4-item self-report measure was used at baseline to distinguish 
between both intentional (active) and unintentional (passive) dimensions of non-adherence. 
Statements corresponding to unintentional non-adherence include “I sometimes forget to 
take my pain medicine” and “I am sometimes careless about taking my pain medicine.” 
Statements that correspond to intentional non-adherence include “When I feel better I 
sometimes stop taking my pain medicine” and “If I feel worse when I take the pain 
medicine, sometimes I stop taking it.” The participants were asked to indicate the extent to 
which they agree with each statement on the MMAS 4-point scale. This score for each of the 
four items are aggregated to give a score ranging from 0 to 4, where higher scores indicate 
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higher levels of reported adherence.29 MAMS has established concurrent and predictive 
validity and its Cronbach’s alpha in different studies have ranged 0.61 to 0.86.
Demographic and Illness Variables—Self-reported demographic data were gathered 
on age, gender, self-identified race and ethnicity, marital status, education, income, and type 
of health insurance. Illness-related variables collected from patients’ medical records 
included type of cancer; stage of cancer, time since cancer diagnosis, past history of drug or 
substance abuse, comorbidities, and history of depression.
Statistical Analysis
All data were analyzed using SAS version 9.3.40 A prediction model was constructed using 
a backward elimination method considering as potential predictors all variables that were 
significant at the bivariate level (p-value < 0.2). The backward elimination method involved 
starting with all candidate variables in the model, then deleting the variable (if any) that 
improves the model the most by being deleted, and repeating this process until no further 
improvement is possible (i.e. all remaining variables in the model are significant at the alpha 
= 0.05 level).
Separate models were run for African Americans and Whites to understand unique 
predictors of analgesic adherence. The rational for running separate models by race rather 
than an overall model of adherence was to identify potential intervention targets, which may 
be unique to each subgroup.
To assess potential bias due to confounding, we generated a series of bivariate analyses with 
adherence as the outcome and several key variables obtained at the initial visit as potential 
predictors. All variables that were found to be statistically significant at the 0.2 level were 
then considered as covariates in the final analysis. Once the multivariable model was 
derived, each of the original variables were re-entered into the model, one variable at a time, 
by testing the most significant to least significant variable to allow a previously insignificant 
variable to become significant in the final model and retaining any variable that yielded a P-
value < 0.05.
Furthermore, to assess for potential bias due to lost to follow-up at month 3, we created a 
binary (yes/no) indicator variable for retention. We then ran a series of bivariate analyses 
considering several key variables obtained at the initial visit as potential predictors of 
retention status. We found no statistically significant predictors of dropout, which supports 
the statistical missing at random data assumption, suggesting no significant bias due to 
retention.
Sensitivity Analysis for the Observer Effect—A critique of MEMS monitoring is that 
due to the awareness of being observed, the MEMS monitoring may lead some individuals 
to modify aspects of their medication taking behavior.44, 45 To account for this potential 
source of bias, we created two separate variables to determine the internal consistency 
between the “dose adherence” outcomes containing data from all the days monitored to the 
outcome containing data with the first 30 days of observation removed. The Spearman 
correlation between adherence scores for all days monitored and the adherence scores with 
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the first 30 days excluded was 0.97 (p < 0.001) for African Americans and 0.95 (p < 0.001) 
for Whites.
Because all Spearman correlations were significantly large, there was strong internal 
consistency between total adherence scores and the total adherence scores with the first 30 
days of observations removed. Similar trends in parameter estimates were observed when 
the outcome with first 30 days removed was used with little difference in the available data 
between the all monitored data and 30 days of observations removed. Based on this, the 
outcome containing the adherence scores for all days monitored was chosen for the final 
analysis.
Results
Figure 1 presents participant and recruitment flowchart. Adherence data using MEMS were 
available for 207 patients (non-Hispanic Whites =121; non-Hispanic African Americans = 
86). There was no differential attrition from T1 to T2 based on key variables such as race 
(P=0.496) or participants’ general health status (P=0.612). The mean age of the group was 
54 years (SD=11). There were significant differences between African Americans and 
Whites based on education, income, type of health insurance, and presence of metastasis 
(Table 1). However, there were no significant differences between the groups based on age, 
gender, type of cancer, time since cancer diagnosis, comorbidity burden, and past history of 
substance or alcohol abuse (Table 1).
Pain and Analgesic Prescription
When compared to Whites, African Americans reported significantly greater cancer pain 
including higher BPI’s “pain worst” scores (P<.001), higher “pain least” scores indicating 
lower pain relief (P<.001) and negative PMI indicating inadequate analgesic prescription 
given the pain levels (P<.001) (Table 2). There were no differences in African Americans 
and Whites in analgesic prescription according to the WHO analgesic step. However, within 
WHO Step 3 analgesics, African Americans were less likely to be prescribed long acting 
opioids for pain relief (P<.001). There was a significant difference between groups on 
Morisky non-adherence items. More specially, a larger percentage of African Americans 
reported being forgetful (41% vs. 27%, p= .043) and intentionally stopping to take pain 
medicine when feeling better (58% vs. 40%; p= .009).
MEMS Analgesic Adherence
Patients’ adherence was monitored for an average of 88 days (SD=17) using MEMS. There 
was no difference between African Americans and Whites in the number and frequency of 
medication changes during the index period (Table 2). However, there were considerable 
differences between African Americans and Whites in the overall analgesic adherence (53% 
vs. 74%, P< .001) as well as adherence according to the WHO analgesic step (Table 2). On 
sub-analysis, analgesic adherence rates for African Americans ranged from 34% (for weak 
opioids) to 63% for long acting opioids. For Whites, adherence ranged from 55% (for weak 
opioids) to 78% for long acting opioids (see Figure 2).
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Unique Predictors of MEMS Analgesic Adherence
Tables 3 and 4 present the findings of the unique predictors of overall adherence (dose 
adherence) for African Americans and Whites, respectively.
African Americans—Income level was the strongest predictor of analgesic adherence for 
cancer pain among African Americans (Table 3). Compared to those who reported a 
household income of more than $50,000 a year, those between $10,000 and $50,000 a year 
had a 25.89 lower percentage of adherence (P=0.002) and those with less than $10,000 a 
year had a 41.83 lower percentage of dose adherence (P< 0.001). Also, clinical variables 
were significant in explaining non-adherence in African Americans. For instance, for each 
unit increase in the severity of analgesic side effects, the percentage of dose adherence 
decreased by 1.39 (P<0.001). Similarly, for each unit increase in the concern of distracting 
doctor from curing the disease, the percentage of dose adherence decreased by 7.44 (P= 
0.002). The Morisky subscale of intentional non-adherence was also a strong predictor of 
dose adherence for African Americans. Those who reported intentional non-adherence (i.e., 
stopping to use analgesics when feeling better), had a −22.17 lower percentage of dose 
adherence (P< 0.001). On the other hand, number of analgesic side-effects reported and 
number of analgesics prescribed were associated positively with dose adherence. This model 
was statistically significant and explained 44% of the variance for dose adherence for 
African Americans.
Whites—Intentional non-adherence subscale (i.e., stopping to use prescribed analgesics 
when feeling better or worse) was the strongest predictor of dose adherence for Whites 
(Table 4). Those who reported stopping to use analgesics when feeling better had a 23.67 
lower percentage of dose adherence (P< 0.001). Similarly, those who reported stopping to 
use analgesics when feeling worse, had a 18.56 lower percentage of dose adherence (P= 
0.010). Clinical variables such as length of pain due to cancer and pain levels also predicted 
dose adherence for Whites. For every unit increase in time since cancer diagnosis (in 
months), dose adherence increased by 0.16 percent (P=0.026). Whereas for every unit 
increase in “pain least” (higher scores indicate lower pain relief), the percentage of dose 
adherence decreased by 2.88 (P= 0.041). This model was statistically significant and 
explained 30% of the variance for dose adherence for Whites.
Discussion
“Drugs don’t work in patients who don’t take them” (C. Everett Koop). By the same token, 
not taking medication is a behavioral representation of what may be right or wrong for the 
patient in a medication treatment setting. We found that analgesic adherence was low for 
both Whites and African Americans but it was considerably lower for African Americans.
Most existing interventions to improve cancer pain outcomes are conceived within a 
psychoeducational paradigm, which focuses on knowledge transfer to address attitudes and 
barriers to opioid use.17, 39, 42 A systematic review of the effectiveness of such interventions 
for cancer pain management found that while the interventions improved knowledge about 
cancer pain management in the majority of the studies (73%), most did not improve reported 
adherence to analgesics.35 These findings were confirmed in another meta-analysis that 
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found no benefit of educational interventions on analgesic adherence or pain-related 
interference.5 This indicates that the knowledge path to improving analgesic adherence or 
cancer pain outcomes may be inadequate.
Consitently, we found that most common analgesic-related fears (including addiction 
concerns) did not explain objective analgesic adherence for cancer pain for African 
Americans or Whites. Rather, most of the identified predictors of objective adherence may 
be thought of as circumstantial or experiential likely based on patients’ previous clinical 
experience of cancer pain management or clinician-patient interaction. Further, African 
Americans had more of such barriers (e.g., need for more information about pain 
medications, and fear of distracting or annoying clinicians, and concern for side-effects) 
than Whites.
Similar findings were supported in a previous study of adherence to analgesia for cancer 
pain (employing subjective measures of adherence and African American patients only). 
The authors found that addiction concerns were not correlated with adherence for WHO step 
2 or step 3 analgesics; rather pain intensity, side-effects, and fear of distracting clinicians 
were associated with analgesic adherence in African Americans with cancer pain.38
Similarly, in our study, an increase in the severity of side-effects was associated with lower 
adherence to analgesia for African Americans but not for Whites. Moreover, more adherent 
African Americans reported greater number of analgesic side-effects at baseline suggesting 
disparites in analgesic adverse effects management in African Americans. The higher 
burden of side-effects in African Americans may also be related to the choice of analgesics 
in African Americans. In a recent study, authors found that controlling for the type of health 
insurance, African Americans with cancer pain had 71% lower odds of receiving a 
prescription of oxycodone than White patients (P <.001) and they were more likely to be 
prescribed morphine even in the presence of renal insufficiency.25 Authors further 
demonstrated that the type of analgesics prescribed partially mediated the reported adverse 
analgesic effects.25
Among Whites, lower pain relief (higher pain least scores) predicted lower adherence to 
analgesia whereas length since cancer diagnosis, possibly indicating disease severity, 
predicted greater analgesic adherence. Consistently, in a previous analysis to understand 
trade-offs African Americans and Whites employ in making cancer pain decisions, we found 
that African Americans were more likely to make analgesic use decisions based on side-
effects whereas Whites were more likely to make analgesic use decisions based on amount 
of relief expected from using pain medications.24
Another important finding of this study is the strong negtive linear relationship in the levels 
of income and adherence to analgesia for cancer pain among African Americans. Studies in 
non-pain settings have found that higher out of pocket cost and household income less than 
$20,000 are associated with medication non-adhrence behaviors including decreasing the 
dose or frequency of medications, failing to refill or extending time between the 
refills.15, 36, 37, 46 In the setting where patients refill their pain medications, they may save 
pain medications until they cannot stand pain or hoard pain medications for when pain is 
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severe; a behavior termed medication triaging.21 While studies of medication triaging in the 
context of pain are limited, there is some evidence that patients may be non-adherent to pain 
medications in order to be able to afford medications for other chronic conditions such as 
diabetes.18 Thus, low income patients may compromise on taking pain medications to be 
able to afford medications considered as “more important” or “lifesaving” or even resort to 
less expensive but also less potent over-the counter alternative therapies.18, 21
The fact that African Americans with lower incomes were less adherent, brings to the 
forefront the importance of discussing cost and ability to pay when writing an analgesic 
prescription. In the current clinical scenario, management of multiple conditions and 
symtoms occur in isolation and by multiple health care providers resulting in accumulated 
cost and complexity for the patients. In a national study, majority (two-thirds) of patients 
with chronic illnesses reporting underusing medications due to cost-related concerns never 
discussed these concerns with their clinicians.37 Of those reporting cost-related non-
adhrence said clinicians never asked them about their ability to pay for medications or did 
not believe that clinicians could help.37 Clinicians may take a more proactive role in 
assessing cost-related issues potentially contributing to analgesic non-adherence and provide 
assistance such as reviewing overall medication regimens, simpligying regimens, changing 
medications to less expensive alternatives when clinically appropriate, or providing 
information about programs that may assist with prescription medication cost.
Finally, consistent with Rhee et al., study,38 overuse of analgesia among African Americans 
is not supported in our study. Unlike adherence for some other chronic conditions where 
there is more agreement on adherence cut-off rates, there is no agreement about which cut-
off is valid for analgesic use for cancer pain.34 Previous studies have employed 70%32 to 
100%33, 34 and in a non-U.S. study However, regardless of the cut-off used, the analgesic 
adherence rates of 34%–63% in African Americans are considerably lower. Similar lower 
analgesic adherence rates for cancer pain in African Americans were also identified in 
another study (46%)38 even using subjective measures that typically overestimate 
adherence. These findings should be a call for concern for the goal of achieving equity in 
clinical cancer pain outcomes.
Strengths and Limitations
This is the first study to our knowledge that has compared adherence to analgesia for cancer 
pain and its unique predictors between African Americans and Whites while employing 
objective measures of adherence over time. However, some findings of our study are 
limited. First, we limited objective monitoring of analgesics to one ATC analgesic. Since we 
used MEMS vial for electronic monitoring, it was not feasible to monitor ATC prescription 
in a patch form. However, we have no reason to believe that analgesics in a patch form 
would be prescribed disproportionately to African Americans- an assumption that is needed 
to nullify our findings of differential prescription of long acting opioids by race.
Furthermore, while MEMS allows for long-term assessment of adherence and detailed 
information about patterns of prescription use, it does not guarantee ingestion of medication. 
Vial opening other than for medication taking, medication changes within the study period, 
and medication holidays (e.g., secondary to hospitalization) may result in inaccuracies in 
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adherence measurement. We minimized this potential source of bias by accounting for cap 
openings other than for medication taking (e.g., for refills), a change in frequency and dose 
of analgesics during the study period, or medication holidays due to hospitalizations (see 
study measures). Despite these limitations, studies in non-cancer pain setting comparing 
MEMS with a variety of subjective measures have concluded that MEMS is one of the more 
accurate adherence measurement approaches.6
Our study is limited in that there were unmeasured cancer (cancer treatment, medications 
other than analgesics and co-analgesics, caner treatment related side-effects, cancer-related 
functional impairments), and psychiatric variables (such as cancer-related anxiety, cancer 
treatment-related posttraumatic symptoms) that may confound the findings. Furthermore, we 
included history of depression from patients’ medical records and did not use self-report 
measure of depression. Also, to create predictive models, we used self-reported data from 
baseline. Since our main goal was to assess patients’ actual adherence behaviors, we 
believed that multiple contacts by the study staff would create an observational effect 
resulting in alteration of patient’s actual behavior. It is conceivable that some of the 
predictors of interest changed over the 3-month course of the study. Finally, although we 
computed PMI for adequacy of analgesic prescription given patient’s levels of pain, we did 
not compare doses of analgesics between African Americans and Whites. Despite these 
limitations, our findings add to a very scarce body of literature to understand differences in 
analgesic adherence and preliminary understanding of sources of those differences as a way 
to explain the widely observed clinical disparities in cancer pain outcomes.
Conclusions
Our salient findings indicate that 1) there are significant disparities between African 
Americans and Whites in the treatment of cancer pain and adherence to analgesia captured 
using MEMS over a 3-months period; 2) analgesic-related beliefs commonly implicated in 
analgesic and opioid-related non-adherence (e.g., addiction concerns) do not explain 
objective analgesic taking in both groups; 3) rather, clinical pain management variables 
explain objective analgesic adherence in this sample of African Americans and Whites; 4) 
the unique predictors of analgesic adherence vary by race, specially socioeconomic 
variables, fear of distracting providers, and analgesic side-effects predict analgesic 
adherence for African Americans but not for Whites; 5) these additional variables may 
explain differential analgesic adherence and consequent disparities in cancer pain outcomes 
in African Americans. The greater burden of unmet cancer pain management needs in 
African Americans deserves correspondingly greater attention and perhaps greater intensity 
of interventions with this group, however, majority of the existing interventions have been 
both conceptualized and investigated predominantly with White patients.
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Perspective
Despite evidence of disparities in cancer pain outcomes among African Americans, 
surprisingly little research exists on African Americans’ adherence to analgesia for 
cancer pain. This prospective study employs objective measures to compare adherence to 
prescribed pain medications between African American and White patients with cancer 
pain.
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Figure 1. 
Participant and recruitment flow chart.
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Figure 2. 
MEMS Dose Adherence by Race and Type of Analgesic
WHO = World Health Organization
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Table 1
Demographic and Illness Characteristics (N=207)
Variable Total (N=207) Whites (N=121) African Americans (N=86) p-values†
Mean (SD)
Age 54(11) 54(12) 53(10) .392
Time since cancer diagnosis (months) 37(35) 36(35) 38(36) .784
Charlson Comorbidity Index 4(3) 4(2) 4(3) .260
Frequency (%)
Gender
 Male 90(43) 59(49) 31(36) .069
 Female 117(57) 62(51) 55(64)
Marital Status <.001
 Married 110(53) 84(69) 26(30)
 Separated/Divorced/Widowed 56(27) 19(16) 37(43)
 Never Married 41(20) 18(15) 23(27)
Education .016
 Elementary 3(1) 1(1) 2(2)
 High School 70(34) 35(29) 35(41)
 College/Trade School 101(49) 58(48) 43(50)
 More Than College 33(16) 27(22) 6(7)
Income (US$) <.001
 < 30, 000 73(35) 24(20) 49(57)
 30–50,000 36(17) 15(12) 21(24)
 50–70,000 37(18) 26(21) 11(13)
 70–90,000 24(12) 21(17) 3(3)
 >90,000 37(18) 35(29) 2(2)
Health Insurance <.001
 Private 107(52) 81(68) 26(30)
 Medicaid 27(13) 5(4) 22(26)
 Medicare 41(20) 21(18) 20(23)
 Multiple 25(12) 12(10) 13(15)
 Other 6(3) 1(1) 5(6)
Cancer Type .907
 Lung 32(15) 21(17) 11(13)
 Breast 38(18) 21(17) 17(20)
 Gastrointestinal 31(15) 19(16) 12(14)
Genitourinary/Reproductive 25(12) 15(12) 10(12)
 Multiple Myeloma 34(16) 17(14) 17(20)
 Other Solid tumors 47(23) 28(23) 19(22)
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Variable Total (N=207) Whites (N=121) African Americans (N=86) p-values†
Presence of Metastasis .008
 Yes 148 (72) 95 (78) 53 (62)
 No 59 (28) 26 (22) 33 (38)
History of Substance Abuse .131
 Yes 35(17) 16(13) 19(22)
 No 172(83) 105(87) 67(78)
History Alcohol Abuse .636
 Yes 20(10) 13 (11) 7(8)
 No 187(90) 108 (89) 79(92)
History of Depression .236
 Yes 87(42) 55(45) 32(37)
 No 120(58) 66(55) 54(63)
†p-values are based on t-tests for continuous variables and chi-squared for categorical variables.
WHO =World Health Organization
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Table 2
Analgesic Prescription and Pain Management Variables (N=207)
Variable Total (N=207) Whites (N=121) African Americans (N=86) p-values†
Frequency (%)
Index Analgesic .111
 WHO Step 1 19 (9.2) 7 (5.8) 12 (14.0)
 WHO Step 2 22 (10.6) 12 (9.9) 10 (11.6)
 WHO Step 3 166 (80.2) 102 (84.3) 64 (74.4)
Negative Pain Management Index <.001
 Yes 18 (8.7) 5 (4.13) 13 (15.1)
 No 189 (91.3) 116 (95.9) 73 (84.9)
Prescription of long acting opioids <.001
 Yes 117 (56.5) 82 (67.8) 35 (40.7)
 No 90 (43.5) 39 (32.2) 51 (59.3)
MMAS unintentional; forgetfulness
 Yes 68 (32.9) 33 (27.3) 35 (40.7) 0.043
 No 139 (67.1) 88 (72.7) 51 (59.3)
MMAS unintentional; carelessness
 Yes 35 (16.9) 21 (17.4) 14 (16.3) 0.839
 No 172 (83.1) 100 (82.6) 72 (83.7)
MMAS intentional; stop when feel better
 Yes 98 (47.3) 48 (39.7) 50 (58.1) 0.009
 No 109 (52.7) 73 (60.3) 36 (41.9)
MMAS intentional; stop when feel worse
 Yes 34 (16.4) 19 (15.7) 15 (17.4) 0. 739
 No 173 (83.6) 102 (84.3) 71 (82.6)
Mean (SD)
Pain worst (BPI, 0–10) 6.4(3) 5.9(3) 7.0(2) <.001
Pain least (BPI, 0–10) 3.3(2) 2.8 (2) 4.0(2) <.001
Pain average (BPI, 0–10) 4.7(2) 4.1(2) 5.3(2) <.001
Pain interference (BPI, 0–70) 35.2(16) 33.6 (15) 37.6(16) .086
Severity of side-effects (MSEC, 0–80) 25.2 (15) 23.8 (13) 27.1(17) .130
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Variable Total (N=207) Whites (N=121) African Americans (N=86) p-values†
Barriers Questionnaire (BQ-II, 0–135) 66.8 (20) 64.5(19) 70.0 (21) .052
Number of index medication changes during the study 
period
.05 (0.24) .06 (0.23) .05 (0.26) .744
Number of medication frequency changes during the study 
period
.14 (0.40) 0.18 (0.46) .09 (0.29) .094
Total number of analgesics prescribed (excluding co-
analgesics)
2.1 (0. 80) 2.1 (0.79) 2.0 (082) .711
Total number co-analgesics prescribed 0.24 (0.50) 0.24 (0.51) 0.23 (0.47) .920
% Overall adherence 65.1 (34.5) 73.7 (31.5) 52.8 (34.9) <.001
Number of MEMS days monitored 87.6(16.7) 86.8 (15.5) 88.4(17.9) .486
% Adherence by WHO step
 WHO Step 1 50.6 (33.5) 59.5 (37.5) 45.4 (31.5) .391
 WHO Step 2 45.2 (31.8) 54.9 (28.6) 33.6 (33.0) .121
 WHO Step 3 69.3 (33.7) 76.9 (30.7) 57.3 (35.1) .000
% Adherence by long acting opioids only 73.6 (31.0) 78.1 (29.2) 62.9 (32.9) .015
†p-values are based on t-tests for continuous variables and chi-squared for categorical variables.
BPI= Brief Pain Inventory; Morisky Medication Adherence Scale; MSEC= Medication Side-effects Checklist; BQ= Barriers Questionnaire; WHO 
=World Health Organization
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Table 3
Unique Predictors of Analgesic Adherence for African Americans
Variable Beta Coefficients* Standard Error P-Value
Household Income
 <$10,000 −41.828 9.207 <0.001
 $10,000–$50,000 −25.894 8.188 0.002
 >$50,000 (reference) ------ ------ ------
Feel the need to receive further information about pain medication
 Yes 25.629 9.381 0.008
 No (reference) ------ ------ ------
Intentional non-adherence (When I feel better I sometimes stop taking my pain 
medicine)
 Yes −22.174 6.131 <0.001
 No (reference) ------ ------ ------
Total number of analgesics prescribed (excluding co-analgesics) 10.720 3.836 0.007
Number of analgesic side-effects 9.812 2.675 <0.001
Fear that if doctors have to deal with pain they won’t concentrate on curing the disease 
(0 = do not agree at all, 5 = agree very much)
−7.440 2.256 0.002
Fear that doctors might find it annoying to be told about pain (0 = do not agree at all, 5 
= agree very much)
5.911 2.394 0.016
Severity of analgesic side-effects −1.389 0.406 <0.001
Model: (F(9,76) = 6.65, p < 0.001, R2 = 0.441)
MEMS =Medication Event Monitoring System
*
The beta coefficients from the final prediction model represent slope coefficients for the continuous predictors, and the difference from the 
reference category for the categorical predictors. A large value implies a large effect size.
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Table 4
Unique Predictors of Analgesic Adherence for Whites
Variable Beta coefficients Standard Error P-Value
Intentional non-adherence (when I feel better I sometimes stop taking my pain medicine)
 Yes −23.672 5.315 <0.001
 No (reference) ------ ------ ------
Intentional non-adherence (if I feel worse when I take the pain medicine, sometimes I 
stop taking it)
 Yes −18.557 7.054 0.010
 No (reference) ------ ------ ------
Pain “least” in last week (0 = no pain, 10 = pain as bad as you can imagine) −2.876 1.394 0.041
Length it has been since the diagnosis of cancer (months) 0.160 0.071 0.026
Model: (F(4,116) = 12.34, p < 0.001, R2 = 0.299)
MEMS =Medication Event Monitoring System
*
The beta coefficients from the final prediction model represent slope coefficients for the continuous predictors, and the difference from the 
reference category for the categorical predictors. A large value implies a large effect size.
J Pain. Author manuscript; available in PMC 2016 September 01.
